The global Immune-mediated Necrotizing Myopathy Treatment market was valued at US$ million in 2023 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2023, While China is to reach $ Million.
Steroids Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of Immune-mediated Necrotizing Myopathy Treatment include GlaxoSmithKline plc, Dr. Reddy's Laboratories, Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.), Hetero Drugs Limited, AbbVie Inc., Teva Pharmaceutical Industries and Novartis AG, etc. in 2023, the global top five players have a share approximately % in terms of revenue.
This report aims to provide a comprehensive presentation of the global market for Immune-mediated Necrotizing Myopathy Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Immune-mediated Necrotizing Myopathy Treatment. This report contains market size and forecasts of Immune-mediated Necrotizing Myopathy Treatment in global, including the following market information:
Global Immune-mediated Necrotizing Myopathy Treatment Market Revenue, 2019-2024, 2025-2030, ($ millions)
Global top five companies in 2023 (%)
We surveyed the Immune-mediated Necrotizing Myopathy Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Immune-mediated Necrotizing Myopathy Treatment Market, by Type, 2019-2024, 2025-2030 ($ millions)
Global Immune-mediated Necrotizing Myopathy Treatment Market Segment Percentages, by Type, 2023 (%)
Steroids
Immunosuppressant
Others
Global Immune-mediated Necrotizing Myopathy Treatment Market, by Application, 2019-2024, 2025-2030 ($ millions)
Global Immune-mediated Necrotizing Myopathy Treatment Market Segment Percentages, by Application, 2023 (%)
Hospital
Clinic
Others
Global Immune-mediated Necrotizing Myopathy Treatment Market, By Region and Country, 2019-2024, 2025-2030 ($ Millions)
Global Immune-mediated Necrotizing Myopathy Treatment Market Segment Percentages, By Region and Country, 2023 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Immune-mediated Necrotizing Myopathy Treatment revenues in global market, 2019-2024 (estimated), ($ millions)
Key companies Immune-mediated Necrotizing Myopathy Treatment revenues share in global market, 2023 (%)
Further, the report presents profiles of competitors in the market, key players include:
GlaxoSmithKline plc
Dr. Reddy's Laboratories
Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.)
Hetero Drugs Limited
AbbVie Inc.
Teva Pharmaceutical Industries
Novartis AG
Outline of Major Chapters:
Chapter 1: Introduces the definition of Immune-mediated Necrotizing Myopathy Treatment, market overview.
Chapter 2: Global Immune-mediated Necrotizing Myopathy Treatment market size in revenue.
Chapter 3: Detailed analysis of Immune-mediated Necrotizing Myopathy Treatment company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Immune-mediated Necrotizing Myopathy Treatment in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Immune-mediated Necrotizing Myopathy Treatment Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Immune-mediated Necrotizing Myopathy Treatment Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Immune-mediated Necrotizing Myopathy Treatment Overall Market Size
2.1 Global Immune-mediated Necrotizing Myopathy Treatment Market Size: 2023 VS 2030
2.2 Global Immune-mediated Necrotizing Myopathy Treatment Market Size, Prospects & Forecasts: 2019-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Immune-mediated Necrotizing Myopathy Treatment Players in Global Market
3.2 Top Global Immune-mediated Necrotizing Myopathy Treatment Companies Ranked by Revenue
3.3 Global Immune-mediated Necrotizing Myopathy Treatment Revenue by Companies
3.4 Top 3 and Top 5 Immune-mediated Necrotizing Myopathy Treatment Companies in Global Market, by Revenue in 2023
3.5 Global Companies Immune-mediated Necrotizing Myopathy Treatment Product Type
3.6 Tier 1, Tier 2 and Tier 3 Immune-mediated Necrotizing Myopathy Treatment Players in Global Market
3.6.1 List of Global Tier 1 Immune-mediated Necrotizing Myopathy Treatment Companies
3.6.2 List of Global Tier 2 and Tier 3 Immune-mediated Necrotizing Myopathy Treatment Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Immune-mediated Necrotizing Myopathy Treatment Market Size Markets, 2023 & 2030
4.1.2 Steroids
4.1.3 Immunosuppressant
4.1.4 Others
4.2 By Type - Global Immune-mediated Necrotizing Myopathy Treatment Revenue & Forecasts
4.2.1 By Type - Global Immune-mediated Necrotizing Myopathy Treatment Revenue, 2019-2024
4.2.2 By Type - Global Immune-mediated Necrotizing Myopathy Treatment Revenue, 2025-2030
4.2.3 By Type - Global Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2019-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Immune-mediated Necrotizing Myopathy Treatment Market Size, 2023 & 2030
5.1.2 Hospital
5.1.3 Clinic
5.1.4 Others
5.2 By Application - Global Immune-mediated Necrotizing Myopathy Treatment Revenue & Forecasts
5.2.1 By Application - Global Immune-mediated Necrotizing Myopathy Treatment Revenue, 2019-2024
5.2.2 By Application - Global Immune-mediated Necrotizing Myopathy Treatment Revenue, 2025-2030
5.2.3 By Application - Global Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2019-2030
6 Sights by Region
6.1 By Region - Global Immune-mediated Necrotizing Myopathy Treatment Market Size, 2023 & 2030
6.2 By Region - Global Immune-mediated Necrotizing Myopathy Treatment Revenue & Forecasts
6.2.1 By Region - Global Immune-mediated Necrotizing Myopathy Treatment Revenue, 2019-2024
6.2.2 By Region - Global Immune-mediated Necrotizing Myopathy Treatment Revenue, 2025-2030
6.2.3 By Region - Global Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2019-2030
6.3 North America
6.3.1 By Country - North America Immune-mediated Necrotizing Myopathy Treatment Revenue, 2019-2030
6.3.2 US Immune-mediated Necrotizing Myopathy Treatment Market Size, 2019-2030
6.3.3 Canada Immune-mediated Necrotizing Myopathy Treatment Market Size, 2019-2030
6.3.4 Mexico Immune-mediated Necrotizing Myopathy Treatment Market Size, 2019-2030
6.4 Europe
6.4.1 By Country - Europe Immune-mediated Necrotizing Myopathy Treatment Revenue, 2019-2030
6.4.2 Germany Immune-mediated Necrotizing Myopathy Treatment Market Size, 2019-2030
6.4.3 France Immune-mediated Necrotizing Myopathy Treatment Market Size, 2019-2030
6.4.4 U.K. Immune-mediated Necrotizing Myopathy Treatment Market Size, 2019-2030
6.4.5 Italy Immune-mediated Necrotizing Myopathy Treatment Market Size, 2019-2030
6.4.6 Russia Immune-mediated Necrotizing Myopathy Treatment Market Size, 2019-2030
6.4.7 Nordic Countries Immune-mediated Necrotizing Myopathy Treatment Market Size, 2019-2030
6.4.8 Benelux Immune-mediated Necrotizing Myopathy Treatment Market Size, 2019-2030
6.5 Asia
6.5.1 By Region - Asia Immune-mediated Necrotizing Myopathy Treatment Revenue, 2019-2030
6.5.2 China Immune-mediated Necrotizing Myopathy Treatment Market Size, 2019-2030
6.5.3 Japan Immune-mediated Necrotizing Myopathy Treatment Market Size, 2019-2030
6.5.4 South Korea Immune-mediated Necrotizing Myopathy Treatment Market Size, 2019-2030
6.5.5 Southeast Asia Immune-mediated Necrotizing Myopathy Treatment Market Size, 2019-2030
6.5.6 India Immune-mediated Necrotizing Myopathy Treatment Market Size, 2019-2030
6.6 South America
6.6.1 By Country - South America Immune-mediated Necrotizing Myopathy Treatment Revenue, 2019-2030
6.6.2 Brazil Immune-mediated Necrotizing Myopathy Treatment Market Size, 2019-2030
6.6.3 Argentina Immune-mediated Necrotizing Myopathy Treatment Market Size, 2019-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Immune-mediated Necrotizing Myopathy Treatment Revenue, 2019-2030
6.7.2 Turkey Immune-mediated Necrotizing Myopathy Treatment Market Size, 2019-2030
6.7.3 Israel Immune-mediated Necrotizing Myopathy Treatment Market Size, 2019-2030
6.7.4 Saudi Arabia Immune-mediated Necrotizing Myopathy Treatment Market Size, 2019-2030
6.7.5 UAE Immune-mediated Necrotizing Myopathy Treatment Market Size, 2019-2030
7 Immune-mediated Necrotizing Myopathy Treatment Companies Profiles
7.1 GlaxoSmithKline plc
7.1.1 GlaxoSmithKline plc Company Summary
7.1.2 GlaxoSmithKline plc Business Overview
7.1.3 GlaxoSmithKline plc Immune-mediated Necrotizing Myopathy Treatment Major Product Offerings
7.1.4 GlaxoSmithKline plc Immune-mediated Necrotizing Myopathy Treatment Revenue in Global Market (2019-2024)
7.1.5 GlaxoSmithKline plc Key News & Latest Developments
7.2 Dr. Reddy's Laboratories
7.2.1 Dr. Reddy's Laboratories Company Summary
7.2.2 Dr. Reddy's Laboratories Business Overview
7.2.3 Dr. Reddy's Laboratories Immune-mediated Necrotizing Myopathy Treatment Major Product Offerings
7.2.4 Dr. Reddy's Laboratories Immune-mediated Necrotizing Myopathy Treatment Revenue in Global Market (2019-2024)
7.2.5 Dr. Reddy's Laboratories Key News & Latest Developments
7.3 Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.)
7.3.1 Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Company Summary
7.3.2 Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Business Overview
7.3.3 Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Immune-mediated Necrotizing Myopathy Treatment Major Product Offerings
7.3.4 Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Immune-mediated Necrotizing Myopathy Treatment Revenue in Global Market (2019-2024)
7.3.5 Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Key News & Latest Developments
7.4 Hetero Drugs Limited
7.4.1 Hetero Drugs Limited Company Summary
7.4.2 Hetero Drugs Limited Business Overview
7.4.3 Hetero Drugs Limited Immune-mediated Necrotizing Myopathy Treatment Major Product Offerings
7.4.4 Hetero Drugs Limited Immune-mediated Necrotizing Myopathy Treatment Revenue in Global Market (2019-2024)
7.4.5 Hetero Drugs Limited Key News & Latest Developments
7.5 AbbVie Inc.
7.5.1 AbbVie Inc. Company Summary
7.5.2 AbbVie Inc. Business Overview
7.5.3 AbbVie Inc. Immune-mediated Necrotizing Myopathy Treatment Major Product Offerings
7.5.4 AbbVie Inc. Immune-mediated Necrotizing Myopathy Treatment Revenue in Global Market (2019-2024)
7.5.5 AbbVie Inc. Key News & Latest Developments
7.6 Teva Pharmaceutical Industries
7.6.1 Teva Pharmaceutical Industries Company Summary
7.6.2 Teva Pharmaceutical Industries Business Overview
7.6.3 Teva Pharmaceutical Industries Immune-mediated Necrotizing Myopathy Treatment Major Product Offerings
7.6.4 Teva Pharmaceutical Industries Immune-mediated Necrotizing Myopathy Treatment Revenue in Global Market (2019-2024)
7.6.5 Teva Pharmaceutical Industries Key News & Latest Developments
7.7 Novartis AG
7.7.1 Novartis AG Company Summary
7.7.2 Novartis AG Business Overview
7.7.3 Novartis AG Immune-mediated Necrotizing Myopathy Treatment Major Product Offerings
7.7.4 Novartis AG Immune-mediated Necrotizing Myopathy Treatment Revenue in Global Market (2019-2024)
7.7.5 Novartis AG Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Immune-mediated Necrotizing Myopathy Treatment Market Opportunities & Trends in Global Market
Table 2. Immune-mediated Necrotizing Myopathy Treatment Market Drivers in Global Market
Table 3. Immune-mediated Necrotizing Myopathy Treatment Market Restraints in Global Market
Table 4. Key Players of Immune-mediated Necrotizing Myopathy Treatment in Global Market
Table 5. Top Immune-mediated Necrotizing Myopathy Treatment Players in Global Market, Ranking by Revenue (2023)
Table 6. Global Immune-mediated Necrotizing Myopathy Treatment Revenue by Companies, (US$, Mn), 2019-2024
Table 7. Global Immune-mediated Necrotizing Myopathy Treatment Revenue Share by Companies, 2019-2024
Table 8. Global Companies Immune-mediated Necrotizing Myopathy Treatment Product Type
Table 9. List of Global Tier 1 Immune-mediated Necrotizing Myopathy Treatment Companies, Revenue (US$, Mn) in 2023 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Immune-mediated Necrotizing Myopathy Treatment Companies, Revenue (US$, Mn) in 2023 and Market Share
Table 11. By Type ? Global Immune-mediated Necrotizing Myopathy Treatment Revenue, (US$, Mn), 2023 & 2030
Table 12. By Type - Immune-mediated Necrotizing Myopathy Treatment Revenue in Global (US$, Mn), 2019-2024
Table 13. By Type - Immune-mediated Necrotizing Myopathy Treatment Revenue in Global (US$, Mn), 2025-2030
Table 14. By Application ? Global Immune-mediated Necrotizing Myopathy Treatment Revenue, (US$, Mn), 2023 & 2030
Table 15. By Application - Immune-mediated Necrotizing Myopathy Treatment Revenue in Global (US$, Mn), 2019-2024
Table 16. By Application - Immune-mediated Necrotizing Myopathy Treatment Revenue in Global (US$, Mn), 2025-2030
Table 17. By Region ? Global Immune-mediated Necrotizing Myopathy Treatment Revenue, (US$, Mn), 2023 & 2030
Table 18. By Region - Global Immune-mediated Necrotizing Myopathy Treatment Revenue (US$, Mn), 2019-2024
Table 19. By Region - Global Immune-mediated Necrotizing Myopathy Treatment Revenue (US$, Mn), 2025-2030
Table 20. By Country - North America Immune-mediated Necrotizing Myopathy Treatment Revenue, (US$, Mn), 2019-2024
Table 21. By Country - North America Immune-mediated Necrotizing Myopathy Treatment Revenue, (US$, Mn), 2025-2030
Table 22. By Country - Europe Immune-mediated Necrotizing Myopathy Treatment Revenue, (US$, Mn), 2019-2024
Table 23. By Country - Europe Immune-mediated Necrotizing Myopathy Treatment Revenue, (US$, Mn), 2025-2030
Table 24. By Region - Asia Immune-mediated Necrotizing Myopathy Treatment Revenue, (US$, Mn), 2019-2024
Table 25. By Region - Asia Immune-mediated Necrotizing Myopathy Treatment Revenue, (US$, Mn), 2025-2030
Table 26. By Country - South America Immune-mediated Necrotizing Myopathy Treatment Revenue, (US$, Mn), 2019-2024
Table 27. By Country - South America Immune-mediated Necrotizing Myopathy Treatment Revenue, (US$, Mn), 2025-2030
Table 28. By Country - Middle East & Africa Immune-mediated Necrotizing Myopathy Treatment Revenue, (US$, Mn), 2019-2024
Table 29. By Country - Middle East & Africa Immune-mediated Necrotizing Myopathy Treatment Revenue, (US$, Mn), 2025-2030
Table 30. GlaxoSmithKline plc Company Summary
Table 31. GlaxoSmithKline plc Immune-mediated Necrotizing Myopathy Treatment Product Offerings
Table 32. GlaxoSmithKline plc Immune-mediated Necrotizing Myopathy Treatment Revenue (US$, Mn) & (2019-2024)
Table 33. GlaxoSmithKline plc Key News & Latest Developments
Table 34. Dr. Reddy's Laboratories Company Summary
Table 35. Dr. Reddy's Laboratories Immune-mediated Necrotizing Myopathy Treatment Product Offerings
Table 36. Dr. Reddy's Laboratories Immune-mediated Necrotizing Myopathy Treatment Revenue (US$, Mn) & (2019-2024)
Table 37. Dr. Reddy's Laboratories Key News & Latest Developments
Table 38. Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Company Summary
Table 39. Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Immune-mediated Necrotizing Myopathy Treatment Product Offerings
Table 40. Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Immune-mediated Necrotizing Myopathy Treatment Revenue (US$, Mn) & (2019-2024)
Table 41. Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Key News & Latest Developments
Table 42. Hetero Drugs Limited Company Summary
Table 43. Hetero Drugs Limited Immune-mediated Necrotizing Myopathy Treatment Product Offerings
Table 44. Hetero Drugs Limited Immune-mediated Necrotizing Myopathy Treatment Revenue (US$, Mn) & (2019-2024)
Table 45. Hetero Drugs Limited Key News & Latest Developments
Table 46. AbbVie Inc. Company Summary
Table 47. AbbVie Inc. Immune-mediated Necrotizing Myopathy Treatment Product Offerings
Table 48. AbbVie Inc. Immune-mediated Necrotizing Myopathy Treatment Revenue (US$, Mn) & (2019-2024)
Table 49. AbbVie Inc. Key News & Latest Developments
Table 50. Teva Pharmaceutical Industries Company Summary
Table 51. Teva Pharmaceutical Industries Immune-mediated Necrotizing Myopathy Treatment Product Offerings
Table 52. Teva Pharmaceutical Industries Immune-mediated Necrotizing Myopathy Treatment Revenue (US$, Mn) & (2019-2024)
Table 53. Teva Pharmaceutical Industries Key News & Latest Developments
Table 54. Novartis AG Company Summary
Table 55. Novartis AG Immune-mediated Necrotizing Myopathy Treatment Product Offerings
Table 56. Novartis AG Immune-mediated Necrotizing Myopathy Treatment Revenue (US$, Mn) & (2019-2024)
Table 57. Novartis AG Key News & Latest Developments
List of Figures
Figure 1. Immune-mediated Necrotizing Myopathy Treatment Segment by Type in 2023
Figure 2. Immune-mediated Necrotizing Myopathy Treatment Segment by Application in 2023
Figure 3. Global Immune-mediated Necrotizing Myopathy Treatment Market Overview: 2023
Figure 4. Key Caveats
Figure 5. Global Immune-mediated Necrotizing Myopathy Treatment Market Size: 2023 VS 2030 (US$, Mn)
Figure 6. Global Immune-mediated Necrotizing Myopathy Treatment Revenue, 2019-2030 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Immune-mediated Necrotizing Myopathy Treatment Revenue in 2023
Figure 8. By Type - Global Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2019-2030
Figure 9. By Application - Global Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2019-2030
Figure 10. By Type - Global Immune-mediated Necrotizing Myopathy Treatment Revenue, (US$, Mn), 2023 & 2030
Figure 11. By Type - Global Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2019-2030
Figure 12. By Application - Global Immune-mediated Necrotizing Myopathy Treatment Revenue, (US$, Mn), 2023 & 2030
Figure 13. By Application - Global Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2019-2030
Figure 14. By Region - Global Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2019-2030
Figure 15. By Country - North America Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2019-2030
Figure 16. US Immune-mediated Necrotizing Myopathy Treatment Revenue, (US$, Mn), 2019-2030
Figure 17. Canada Immune-mediated Necrotizing Myopathy Treatment Revenue, (US$, Mn), 2019-2030
Figure 18. Mexico Immune-mediated Necrotizing Myopathy Treatment Revenue, (US$, Mn), 2019-2030
Figure 19. By Country - Europe Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2019-2030
Figure 20. Germany Immune-mediated Necrotizing Myopathy Treatment Revenue, (US$, Mn), 2019-2030
Figure 21. France Immune-mediated Necrotizing Myopathy Treatment Revenue, (US$, Mn), 2019-2030
Figure 22. U.K. Immune-mediated Necrotizing Myopathy Treatment Revenue, (US$, Mn), 2019-2030
Figure 23. Italy Immune-mediated Necrotizing Myopathy Treatment Revenue, (US$, Mn), 2019-2030
Figure 24. Russia Immune-mediated Necrotizing Myopathy Treatment Revenue, (US$, Mn), 2019-2030
Figure 25. Nordic Countries Immune-mediated Necrotizing Myopathy Treatment Revenue, (US$, Mn), 2019-2030
Figure 26. Benelux Immune-mediated Necrotizing Myopathy Treatment Revenue, (US$, Mn), 2019-2030
Figure 27. By Region - Asia Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2019-2030
Figure 28. China Immune-mediated Necrotizing Myopathy Treatment Revenue, (US$, Mn), 2019-2030
Figure 29. Japan Immune-mediated Necrotizing Myopathy Treatment Revenue, (US$, Mn), 2019-2030
Figure 30. South Korea Immune-mediated Necrotizing Myopathy Treatment Revenue, (US$, Mn), 2019-2030
Figure 31. Southeast Asia Immune-mediated Necrotizing Myopathy Treatment Revenue, (US$, Mn), 2019-2030
Figure 32. India Immune-mediated Necrotizing Myopathy Treatment Revenue, (US$, Mn), 2019-2030
Figure 33. By Country - South America Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2019-2030
Figure 34. Brazil Immune-mediated Necrotizing Myopathy Treatment Revenue, (US$, Mn), 2019-2030
Figure 35. Argentina Immune-mediated Necrotizing Myopathy Treatment Revenue, (US$, Mn), 2019-2030
Figure 36. By Country - Middle East & Africa Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2019-2030
Figure 37. Turkey Immune-mediated Necrotizing Myopathy Treatment Revenue, (US$, Mn), 2019-2030
Figure 38. Israel Immune-mediated Necrotizing Myopathy Treatment Revenue, (US$, Mn), 2019-2030
Figure 39. Saudi Arabia Immune-mediated Necrotizing Myopathy Treatment Revenue, (US$, Mn), 2019-2030
Figure 40. UAE Immune-mediated Necrotizing Myopathy Treatment Revenue, (US$, Mn), 2019-2030
Figure 41. GlaxoSmithKline plc Immune-mediated Necrotizing Myopathy Treatment Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 42. Dr. Reddy's Laboratories Immune-mediated Necrotizing Myopathy Treatment Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 43. Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Immune-mediated Necrotizing Myopathy Treatment Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 44. Hetero Drugs Limited Immune-mediated Necrotizing Myopathy Treatment Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 45. AbbVie Inc. Immune-mediated Necrotizing Myopathy Treatment Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 46. Teva Pharmaceutical Industries Immune-mediated Necrotizing Myopathy Treatment Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 47. Novartis AG Immune-mediated Necrotizing Myopathy Treatment Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
